Inozyme Pharma Stock Performance
| INZY Stock | USD 1.46 0.04 2.82% |
The company retains a Market Volatility (i.e., Beta) of 0.29, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Inozyme Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Inozyme Pharma is expected to be smaller as well. At this point, Inozyme Pharma has a negative expected return of -1.6%. Please make sure to check out Inozyme Pharma's kurtosis, and the relationship between the maximum drawdown and rate of daily change , to decide if Inozyme Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Inozyme Pharmas Buy Rating Reaffirmed at Needham Company LLC - MarketBeat | 11/06/2024 |
2 | Inozyme Pharma to Present at Upcoming Investor Conferences | 11/11/2024 |
3 | Eventide Asset Managements Strategic Acquisition of Inozyme Pharma Shares | 11/14/2024 |
4 | Heres Why Inozyme Pharma is Poised for a Turnaround After Losing -29.98 percent in 4 Weeks - MSN | 11/20/2024 |
5 | Acquisition by Sullivan Lynne Marie of 9367 shares of Inozyme Pharma subject to Rule 16b-3 | 11/22/2024 |
6 | Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference | 11/27/2024 |
7 | Sphera Funds Management LTD. Has 6.23 Million Stake in Inozyme Pharma, Inc. | 12/05/2024 |
8 | Jefferies initiates Buy rating on Inozyme Pharma stock, highlights potential of INZ-701 - Investing.com | 12/12/2024 |
9 | Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates | 01/10/2025 |
10 | HC Wainwright Predicts Inozyme Pharma Q1 Earnings | 01/15/2025 |
11 | Disposition of 25000 shares by Douglas Treco of Inozyme Pharma subject to Rule 16b-3 | 01/27/2025 |
| Begin Period Cash Flow | 33.3 M |
Inozyme |
Inozyme Pharma Relative Risk vs. Return Landscape
If you would invest 436.00 in Inozyme Pharma on November 1, 2024 and sell it today you would lose (290.00) from holding Inozyme Pharma or give up 66.51% of portfolio value over 90 days. Inozyme Pharma is currently does not generate positive expected returns and assumes 6.1829% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Inozyme, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Inozyme Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inozyme Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inozyme Pharma, and traders can use it to determine the average amount a Inozyme Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2592
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INZY |
Estimated Market Risk
| 6.18 actual daily | 55 55% of assets are less volatile |
Expected Return
| -1.6 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.26 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Inozyme Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inozyme Pharma by adding Inozyme Pharma to a well-diversified portfolio.
Inozyme Pharma Fundamentals Growth
Inozyme Stock prices reflect investors' perceptions of the future prospects and financial health of Inozyme Pharma, and Inozyme Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inozyme Stock performance.
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 8.97 M | ||||
| Shares Outstanding | 64.24 M | ||||
| Price To Book | 1.13 X | ||||
| EBITDA | (74.81 M) | ||||
| Net Income | (71.17 M) | ||||
| Cash And Equivalents | 151.48 M | ||||
| Cash Per Share | 3.77 X | ||||
| Total Debt | 46.59 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.54 X | ||||
| Book Value Per Share | 1.29 X | ||||
| Cash Flow From Operations | (70.67 M) | ||||
| Earnings Per Share | (1.55) X | ||||
| Market Capitalization | 93.79 M | ||||
| Total Asset | 200.85 M | ||||
| Retained Earnings | (285.93 M) | ||||
| Working Capital | 181.56 M | ||||
About Inozyme Pharma Performance
Evaluating Inozyme Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Inozyme Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Inozyme Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (32.10) | (33.70) | |
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.47) | (0.49) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.58) | (0.55) |
Things to note about Inozyme Pharma performance evaluation
Checking the ongoing alerts about Inozyme Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inozyme Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inozyme Pharma generated a negative expected return over the last 90 days | |
| Inozyme Pharma has high historical volatility and very poor performance | |
| Inozyme Pharma may become a speculative penny stock | |
| Inozyme Pharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (71.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Inozyme Pharma currently holds about 151.48 M in cash with (70.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Inozyme Pharma has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 25000 shares by Douglas Treco of Inozyme Pharma subject to Rule 16b-3 |
- Analyzing Inozyme Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inozyme Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Inozyme Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inozyme Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inozyme Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inozyme Pharma's stock. These opinions can provide insight into Inozyme Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.